Although immunotherapy has shown promising results in the treatment of certain breast cancer subtypes, such as triple negative breast cancer, its efficacy in hormone receptor-positive subtypes, such as hormone receptor+/HER2−, remains limited. Here, NR4A1 is linked to breast cancer.